Introduction
The ability (non-ts phenotype, temperature resistance) or inability (ts phenotype, temperature sensitivity) to grow at elevated temperature is an important characteristics of wild type viruses. Previously, it has been shown that the temperature sensitive characteristics of past influenza viruses exhibited a cyclical pattern. 1 New antigenic shift ⁄ drift variants causing pandemics or large epidemics typically displayed a non-ts phenotype while at the end of the circulation non-ts strains were replaced with antigenically related but temperature sensitive (ts) strains 2 which changed later to novel non-ts viruses possessing different antigenic properties. It appears that the ts phenotype of circulating strains depends on the viruses being antigenically novel for humans. It seems that analysis of the temperature sensitive phenotype may help to evaluate the pandemic potential of circulating viruses and predict appearance of new epidemic or pandemic strain.
The 2009 novel A(H1N1) virus which is causing infection among humans was shown to be genetically related to recent swine influenza viruses, but doesn't have the genetic makeup previously detected among viruses infecting humans or animals. 3, 4 It appears to be more contagious than typical seasonal flu. 5 Today the novel influenza A(H1N1) virus is causing pandemic activity. On 11 June 2009, WHO announced that the level of influenza alert was raised from phase 5 to 6 and now we are in the first stages of the pandemic. 6 Influenza vaccination is the primary method for preventing influenza. Live, attenuated cold-adapted reassortant influenza vaccines are currently licensed in the Russian Federation and the United States and appear to be safe and efficacious and might possibly provide broader immune responses than inactivated vaccines. As the pandemic virus is available, a rapid evaluation of it's characteristics is needed. For the rapid and successful development of live, attenuated reassortant influenza vaccine, wild type parental virus has to be phenotypically and antigenically different from master donor virus. In this study, we performed an analysis of the phenotypic properties of the novel A(H1N1) virus to evaluate its pandemic potential by phenotypic analysis and characterize this virus as a prototype wild type parent for possible live, attenuated cold-adapted reassortant influenza pandemic vaccine. Hemagglutination test was performed at room temperature with 1% suspension of chicken, human 0(I) Rh+ and guinea pig red blood cells (RBCs) by a routine technique. 8 Determining ts and ca phenotype The capacity to grow at optimum (33°C), elevated (40°C) and low (25°C) temperatures was studied for A ⁄ California ⁄ 07 ⁄ 2009 (H1N1) influenza virus in comparison with viruses isolated in different years and was determined by titration in eggs. Ts phenotype was expressed as a reduction of virus titer at 40°C from the titer at permissive temperature (33°C). Ca phenotype was expressed as a reduction of virus titer at 25°C from the titer at 33°C. The log EID 50 ⁄ ml calculation was based on the Reed and Muench method. 9 Viruses were considered as non-ts if log EID 50 ⁄ ml at 33°C -log EID 50 ⁄ ml at 40°C £ 3AE0 log EID 50 ⁄ ml. Viruses were considered as non-ca if log EID 50 ⁄ ml at 33°C -log EID 50 ⁄ ml at 25°C ‡ 5AE0 log EID 50 ⁄ ml. The cold-adapted and temperature sensitive A ⁄ Leningrad ⁄ 134 ⁄ 17 ⁄ 57 (H2N2) master donor virus for Russian live, cold-adapted reassortant influenza vaccine was used as a positive control of ts and ca markers.
Methods

Viruses
Hemagglutination inhibition (HAI) test was performed using standard techniques as described 10 in 96-well microtiter plates at room temperature with 1% suspension of human 0(I) Rh+ red blood cells.
Sensitivity to serum inhibitors
For analysis of sensitivity of influenza viruses to non-specific inhibitors, normal (non-immune) horse serum (BioloT, St. Petersburg, Russia), normal rabbit and guinea pig sera (Laboratory Animals Farm ''Rappolovo'', St. Petersburg, Russia) were used. Sera were heat inactivated for 10 min at 80°C to eliminate temperature sensitive inhibitors and used for HAI assay with four hemagglutinating units of tested viruses and for neutralization by animal sera.
Results and discussion
Determining ts and ca phenotype of influenza A viruses
Our previous data provided evidence of the dominance of the ts viruses in circulation prior to the appearance of new antigenic variants in the human population. In contrast, the phenotype of antigenically new viruses was temperature resistant. During circulations they were replaced with antigenically related but temperature sensitive strains which turned later to non-ts viruses possessed different antigenic properties. 1 In this study, we demonstrated that influenza A viruses from recent years such as A ⁄ Malaysia ⁄ 01 ⁄ 04 (H3N2), A ⁄ Brisbane ⁄ 59 ⁄ 2007 (H1N1) or A ⁄ Brisbane ⁄ 10 ⁄ 2007 (H3N2) were temperature sensitive (Table 1) . According to these data we assumed that novel non-ts influenza virus with pandemic ⁄ epidemic potential may appeared in the near future. Results of the phenotypic analysis of the 2009 novel A(H1N1) virus may be considered as direct experimental support for this hypothesis. We demonstrated that ts and ca characteristics of A ⁄ California ⁄ 07 ⁄ 2009 (H1N1) virus are similar to those of past pandemic and epidemic viruses such as A ⁄ Singapore ⁄ 1 ⁄ 57 (H2N2), Table 1) .
Determining the ability of influenza A viruses to agglutinate red blood cells of different origin
The HA protein binds to a sialic acid-containing receptor on the red blood cell surface. The ability of virus strains, necessary for vaccine production, to absorb differrent types of red blood cells must be monitored closely. It is known that some current influenza A(H1N1) viruses have lost the ability to agglutinate chicken red blood cells. For example, some A(H1N1) viruses (A ⁄ Aichi ⁄ 4 ⁄ 92) isolated in Japan during the 1991-1992 season agglutinated chicken RBCs, while other viruses (A ⁄ Aichi ⁄ 24 ⁄ 92) did not. 11 We have studied the ability to agglutinate red blood cells of different origin of some influenza A(H1N1) viruses which were in use at different years as parental viruses for vaccine development. We did not find any significant difference in the ability of the HA of A ⁄ Beijing ⁄ 262 ⁄ 95, A ⁄ New Caledonia ⁄ 20 ⁄ 99 or A ⁄ Perth ⁄ 13 ⁄ 95 influenza viruses to bind chicken, human or guinea pig erythrocytes -they demonstrated equal capability to agglutinate all tested types of RBCs (Table 2 ). The HA protein of novel A ⁄ California ⁄ 07 ⁄ 2009 (H1N1) virus also recognized all tested red blood cells equally. The fact that novel A(H1N1) virus was able to agglutinate RBCs from different animal species efficiently and didn't display preferential tropism made it suitable for vaccine development process.
Determining inhibitor sensitive phenotype of influenza A viruses
The receptor-binding activity of influenza viruses can be inhibited by non-specific inhibitors present in the sera of animals. [12] [13] [14] Normal (non-immune) animal sera contain the temperature stable glycoprotein gamma-inhibitors which inhibit hemagglutinating activity of some influenza viruses. In the current study, the sensitivity of A ⁄ California ⁄ 07 ⁄ 2009 (H1N1) virus to gamma-inhibitors of horse, rabbit and guinea pig sera were compared with inhibitor sensitivity of some past and current influenza A viruses was investigated. No inhibitor activity of horse, rabbit and guinea pig sera was detected in HAI test both for A ⁄ Singapore ⁄ 1 ⁄ 57 (H2N2) or A ⁄ Hong Kong ⁄ 1 ⁄ 68 (H3N2) past pandemic strains and seasonal or current pandemic A(H1N1) viruses tested. In contrast, A ⁄ Malaysia ⁄ 01 ⁄ 04 (H3N2) virus was found to be highly sensitive to inhibitors ( Table 3) . Analogous results to those observed with the HAI assays were obtained with respect to neutralization by animal sera. The pattern of A ⁄ California ⁄ 07 ⁄ 2009 (H1N1) virus sensitivity to neutralization by horse, guinea pig and rabbit sera was studied (Table 4) . A ⁄ Malaysia ⁄ 01 ⁄ 04 (H3N2) virus was taken as a positive control to determine sensitivity to neutralization by animal sera. A ⁄ New Caledonia ⁄ 20 ⁄ 99 (H1N1) was used as a serum resistant control virus.
A virus was considered to be resistant to neutralization by serum if there was <2 log EID 50 ⁄ ml difference between growth of the virus in the presence and in the absence of serum. A virus was designated sensitive to neutralization by serum if there was more than 5 log EID 50 ⁄ ml difference between growth of the virus in the presence and in the absence of serum.
Inhibitor sensitive A ⁄ Malaysia ⁄ 01 ⁄ 04 (H3N2) virus had 5AE5 log EID 50 ⁄ ml reduction in titers when grown in the presence of rabbit serum and 5AE8 log EID 50 ⁄ ml in the presence of horse serum respectively. A ⁄ New Caledonia ⁄ 20 ⁄ 99 (H1N1) virus was resistant to all animal sera tested in the neutralization assay (log reduction of virus titer was 0AE1-0AE5 log EID 50 ⁄ ml). The novel swine-origin A ⁄ California ⁄ 07 ⁄ 2009 (H1N1) virus growing in the presence of rabbit serum displayed clear inhibitor resistant phenotype (log reduction of virus titer was 0AE8 log EID 50 ⁄ ml). Also this virus did not display any significant differences in titers when grown in the absence or in the presence of horse and guinea pig sera (0AE5 and 0AE2 log EID 50 ⁄ ml reduction respectively). Thus, these data confirmed the high inhibitor resistant phenotype of the novel A (H1N1) influenza virus demonstrated in this study by HAI test.
Little is known about inhibitor resistancy of pandemic or epidemic viruses. It doesn't seem that pandemic viruses have to be always inhibitor resistant or sensitive. But in the majority of cases epidemic ⁄ pandemic viruses are non-ts, non-ca, and inhibitor resistant with some exceptions like A ⁄ Malaysia ⁄ 01 ⁄ 04 (H3N2) which is nonca, but ts and inhibitor sensitive. We also registered the appearance of inhibitor sensitive H1N1 viruses and inhibitor resistant H3N2 viruses in inter-epidemic seasons (data not published). Inhibitor studies are important to evaluate the phenotypic characteristics of any antigenically new influenza virus, especially from the LAIV development point of view. Theoretically, inhibitor sensitive vaccine strains could be potentially less effective in comparison with inhibitor resistant strains. Also using inhibitor sensitive circulating viruses as wild type parents for LAIV development may cause difficulties in the process of reassortment because of non-specific inhibition of reassortants possessed wild type HA by serum raised against master donor virus.
Conclusion
Accordingly, it was confirmed that the analyzed phenotypic characteristics of novel swine-origin A ⁄ California ⁄ 07 ⁄ 2009 (H1N1) strain are similar to those of the past pandemic influenza viruses, such as A ⁄ Singapore ⁄ 1 ⁄ 57 (H2N2) or A ⁄ Hong Kong ⁄ 1 ⁄ 68 (H3N2). The A ⁄ California ⁄ 07 ⁄ 2009 (H1N1) influenza strain is serum and temperature resistant and sensitive to grow at low temperature and may be considered as of a good prototype wild type parent for live attenuated cold-adapted reassortant vaccine for potential use for controlling pandemic influenza. nd, not determined. *Serial 10-fold dilutions of the viruses were made in animal serum, diluted 1:10 and heat inactivated 10 min at 80°C (or PBS) at +4°C for 30 min and then inoculated into chicken eggs. Viral growth in eggs was detected using the HA assay with 1% human red blood cells. **From the titer without serum.
